Manipulation of Nitric Oxide Levels via a Modified Hydroxyethyl Starch Molecule.

[1]  Kendra M Barrier.  Summary of the 2016 International Surviving Sepsis Campaign: A Clinician's Guide. , 2018, Critical care nursing clinics of North America.

[2]  C. Ince,et al.  Scavenging reactive oxygen species using tempol in the acute phase of renal ischemia/reperfusion and its effects on kidney oxygenation and nitric oxide levels , 2015, Intensive Care Medicine Experimental.

[3]  C. Ince,et al.  Differentiated control of deranged nitric oxide metabolism: a therapeutic option in sepsis? , 2013, Critical Care.

[4]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[5]  C. Ince,et al.  The acute effects of acetate-balanced colloid and crystalloid resuscitation on renal oxygenation in a rat model of hemorrhagic shock. , 2012, Resuscitation.

[6]  C. Ince,et al.  Balanced vs unbalanced crystalloid resuscitation in a near-fatal model of hemorrhagic shock and the effects on renal oxygenation, oxidative stress, and inflammation. , 2012, Resuscitation.

[7]  C. Ince,et al.  Acute Effects of Balanced Versus Unbalanced Colloid Resuscitation on Renal Macrocirculatory and Microcirculatory Perfusion During Endotoxemic Shock , 2012, Shock.

[8]  Can Ince,et al.  The Microcirculation as a Therapeutic Target in the Treatment of Sepsis and Shock , 2011, Seminars in respiratory and critical care medicine.

[9]  H. Schmidt,et al.  Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. , 2011, American journal of physiology. Heart and circulatory physiology.

[10]  T. Yeo,et al.  Asymmetric Dimethylarginine, Endothelial Nitric Oxide Bioavailability and Mortality in Sepsis , 2011, PloS one.

[11]  M. Berger,et al.  Acute Endotoxemia Inhibits Microvascular Nitric Oxide-Dependent Vasodilation in Humans , 2011, Shock.

[12]  C. Ince,et al.  Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. , 2010, Journal of critical care.

[13]  C. Kevil,et al.  S-Nitrosothiol biology and therapeutic potential in metabolic disease. , 2010, Current opinion in investigational drugs.

[14]  J. Klimas,et al.  Heart rate correction of the QT duration in rats. , 2010, European journal of pharmacology.

[15]  J. Vincent,et al.  Effects of fluids on microvascular perfusion in patients with severe sepsis , 2010, Intensive Care Medicine.

[16]  K. Klingel,et al.  EFFECTS OF 1400W AND/OR NITROGLYCERIN ON RENAL OXYGENATION AND KIDNEY FUNCTION DURING ENDOTOXAEMIA IN ANAESTHETIZED RATS , 2009, Clinical and experimental pharmacology & physiology.

[17]  A. Melamed,et al.  The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data , 2009, Critical care.

[18]  J. Bakker,et al.  The heterogeneity of the microcirculation in critical illness. , 2008, Clinics in chest medicine.

[19]  M. Meade,et al.  NITRIC OXIDE DONORS IN SEPSIS: A SYSTEMATIC REVIEW OF CLINICAL AND IN VIVO PRECLINICAL DATA , 2008, Shock.

[20]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[21]  G. Schmidt,et al.  Impairments in microvascular reactivity are related to organ failure in human sepsis. , 2007, American journal of physiology. Heart and circulatory physiology.

[22]  K. Vollebregt,et al.  The NO donor SIN‐1 improves intestinal–arterial Pco2 gap in experimental endotoxemia: an animal study , 2007, Acta anaesthesiologica Scandinavica.

[23]  Herwig Gerlach,et al.  Fluid resuscitation in severe sepsis and septic shock: An evidence-based review , 2004, Critical care medicine.

[24]  L. Toledo-Pereyra,et al.  Exogenous nitric oxide donor and related compounds protect against lung inflammatory response after hemorrhagic shock and resuscitation. , 2004, The Journal of trauma.

[25]  John A Kellum,et al.  Science review: Extracellular acidosis and the immune response: clinical and physiologic implications , 2004, Critical care.

[26]  P. Moore,et al.  Nitric oxide releasing acetaminophen (nitroacetaminophen). , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[27]  M. Gladwin,et al.  Methodologies for the Sensitive and Specific Measurement of S -nitrosothiols, Iron-nitrosyls, and Nitrite in Biological Samples , 2003, Free radical research.

[28]  C. Ince,et al.  Opening the microcirculation: can vasodilators be useful in sepsis? , 2002, Intensive Care Medicine.

[29]  J. Wallace,et al.  Vasorelaxant effects of a nitric oxide‐releasing aspirin derivative in normotensive and hypertensive rats , 2001, British journal of pharmacology.

[30]  P. K. Moore,et al.  Nitroparacetamol exhibits anti‐inflammatory and anti‐nociceptive activity , 2000, British journal of pharmacology.

[31]  Y. Nakajima,et al.  S-nitroso-N-acetylpenicillamine (SNAP) During Hemorrhagic Shock Improves Mortality as a Result of Recovery From Vascular Hyporeactivity , 2000, Anesthesia and analgesia.

[32]  K. Messmer,et al.  The nitric oxide donor sodium nitroprusside protects against hepatic microcirculatory dysfunction in early endotoxaemia , 1998, Intensive Care Medicine.

[33]  D. Paterson,et al.  Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current, I(f). , 1997, Circulation research.

[34]  E. Troncy,et al.  Effects of reducing reagents and temperature on conversion of nitrite and nitrate to nitric oxide and detection of NO by chemiluminescence. , 1997, Clinical chemistry.

[35]  J. Vincent,et al.  Effects of nitric oxide donor SIN-1 on oxygen availability and regional blood flow during endotoxic shock. , 1996, Archives of surgery.

[36]  A. M. Lefer,et al.  Protective actions of S-nitroso-N-acetylpenicillamine (SNAP) in a rat model of hemorrhagic shock. , 1992, Methods and findings in experimental and clinical pharmacology.

[37]  C. Wilcox.  Regulation of renal blood flow by plasma chloride. , 1983, The Journal of clinical investigation.

[38]  Julio C. B. Ferreira,et al.  Nitroglycerin use in myocardial infarction patients. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[39]  S. Huerta,et al.  Nitric oxide donors: novel cancer therapeutics (review). , 1992 .

[40]  W. Schimetta,et al.  Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters , 2008, Clinical chemistry and laboratory medicine.

[41]  G. Richardson,et al.  Potential therapeutic uses for S-nitrosothiols. , 2002, Clinical science.

[42]  J. Wallace,et al.  In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. , 1999, Thrombosis research.